The University of Cincinnati Cancer Center was granted $2.3 million from NCI to develop a technique to visualize where genetically modified immune cells go in the body after being administered to patients with cancer.
On the evening of Feb. 15, when the dreaded letter of termination arrived, an NCI employee was just a few weeks away from job security—the end of the probationary period.
